drugset / Trial / NCT05431023

Effect of Lactoferrin in Pneumonia Treatment

NCT05431023

Unknown 72 enrolled Assiut University
RandomizedParallel-groupOpen-labelTreatment

Summary

Pneumonia is defind as the inflammation of lung tissue caused by an infectious agent that results in acute respiratory signs and symptoms. Community acquired pneumonia (CAP) is a major cause of morbidity and increased health care costs. In developing nations, pneumonia remains a significant cause of mortality in children. Pneumonia occurs in 30 to 45 of every 1,000 children under 5 years of age; it is less common in 5- to 9-year olds (16 to 22/1,000) and in older children (7 to 16/1,000). Streptococcus pneumoniae is the primary bacterial cause of pneumonia in infants and children. Viral etiologies become less prevalent and mycoplasmal and chlamydial infections become more prevalent with increasing age

Timeline

Start
2022-08-01
Primary completion
2023-08-01
Completion
2024-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactoferrin Protein / enzyme biologic

Indications